USARx offers multiple ways to purchase this medication. Choose the Best option for you!
No38% of Medicare Part D and Medicare Advantage plans cover this drug, so it's pretty much a toss-up.
It depends. Which coverage stage are you in? Click on a tab below…
$15 – $2416
In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.
Here are some ways that may lower the cost of your methyltestosterone prescription.
If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.
Applies to methyltestosterone: oral capsules, oral tablets
Side effects include:
Males: Gynecomastia, frequent or persistent penile erections.
Females: Amenorrhea, other menstrual irregularities, inhibition of gonadotropin secretion, virilization (e.g., deepening of the voice, clitoral enlargement).
Applies to methyltestosterone: compounding powder, oral capsule, oral tablet
The more commonly reported adverse effects of androgen therapy in males is gynecomastia and excessive frequency and duration of penile erections; in women, virilization including voice deepening and clitoral enlargement.
Frequency not reported: Edema with or without congestive heart failure, myocardial infarction, stroke
Postmarketing reports: venous thromboembolic events, including deep vein thrombosis (DVT)
Frequency not reported: Gynecomastia, virilization (women), hirsutism
Rare (less than 0.1%): Peliosis hepatic
Frequency not reported: Cholestatic jaundice, altered liver function
Frequency not reported: Amenorrhea, menstrual irregularities, excessive frequency and duration of penile erections, oligospermia, increased or decreased libido
Frequency not reported: Retention of sodium, chloride, water, potassium, calcium and inorganic phosphates, increased serum cholesterol, hypercalcemia
Frequency not reported: Male pattern baldness, acne
Frequency not reported: Nausea, vomiting
Frequency not reported: acceleration of bone maturation without producing compensatory gain in linear growth resulting in compromised adult stature
Frequency not reported: Suppression of clotting factors II, V, VII, and X; bleeding (in patients on concomitant anticoagulant therapy and polycythemia)
Very rare (less than 0.01%): Anaphylactoid reactions
Frequency not reported: Headache, generalized paresthesia
Rare (less than 0.1%): Hepatocellular neoplasms
Postmarketing reports: venous thromboembolic events, including pulmonary embolism
Frequency not reported: Steroid abuse, anxiety, depression
June 26, 2020
June 25, 2020
June 27, 2020
July 10, 2020
July 9, 2020
July 1, 2020